231 related articles for article (PubMed ID: 18928983)
21. Impact of 17P usage on NICU admissions in a managed medicaid population--a five-year review.
Mason MV; Poole-Yaeger A; Krueger CR; House KM; Lucas B
Manag Care; 2010 Feb; 19(2):46-52. PubMed ID: 20550052
[TBL] [Abstract][Full Text] [Related]
22. The prediction of recurrent preterm birth in patients on 17-alpha-hydroxyprogesterone caproate using serial fetal fibronectin and cervical length.
Romero J; Rebarber A; Saltzman DH; Schwartz R; Peress D; Fox NS
Am J Obstet Gynecol; 2012 Jul; 207(1):51.e1-5. PubMed ID: 22595378
[TBL] [Abstract][Full Text] [Related]
23. Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
Manuck TA; Esplin MS; Biggio J; Bukowski R; Parry S; Zhang H; Huang H; Varner MW; Andrews W; Saade G; Sadovsky Y; Reddy UM; Ilekis J;
Am J Obstet Gynecol; 2016 Mar; 214(3):376.e1-8. PubMed ID: 26692181
[TBL] [Abstract][Full Text] [Related]
24. Twins and preterm labor.
Rust OA; Perry KG; Andrew ME; Roberts WE; Martin RW; Morrison JC
J Reprod Med; 1997 Apr; 42(4):229-34. PubMed ID: 9131496
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness of 17-α-hydroxyprogesterone caproate on preterm birth prevention in women with history-indicated cerclage.
Mackeen AD; Rafael TJ; Zavodnick J; Berghella V
Am J Perinatol; 2013 Oct; 30(9):755-8. PubMed ID: 23341330
[TBL] [Abstract][Full Text] [Related]
26. Relation of body mass index to frequency of recurrent preterm birth in women treated with 17-alpha hydroxyprogesterone caproate.
Co AL; Walker HC; Hade EM; Iams JD
Am J Obstet Gynecol; 2015 Aug; 213(2):233.e1-5. PubMed ID: 25912300
[TBL] [Abstract][Full Text] [Related]
27. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery.
Spong CY; Meis PJ; Thom EA; Sibai B; Dombrowski MP; Moawad AH; Hauth JC; Iams JD; Varner MW; Caritis SN; O'Sullivan MJ; Miodovnik M; Leveno KJ; Conway D; Wapner RJ; Carpenter M; Mercer B; Ramin SM; Thorp JM; Peaceman AM; Gabbe S;
Am J Obstet Gynecol; 2005 Sep; 193(3 Pt 2):1127-31. PubMed ID: 16157124
[TBL] [Abstract][Full Text] [Related]
28. 17 hydroxyprogesterone for the prevention of preterm delivery.
Meis PJ;
Obstet Gynecol; 2005 May; 105(5 Pt 1):1128-35. PubMed ID: 15863556
[TBL] [Abstract][Full Text] [Related]
29. Uterine activity in women receiving 17 alpha-hydroxyprogesterone caproate for the prevention of preterm birth: an observational study.
O'Brien JM; Ho SJ; Istwan NB; Stanziano GJ; Rhea DJ; Barton JR
Am J Perinatol; 2010 Feb; 27(2):157-62. PubMed ID: 19644788
[TBL] [Abstract][Full Text] [Related]
30. Gestational age at initiation of 17-alpha hydroxyprogesterone caproate and recurrent preterm birth.
Ning A; Vladutiu CJ; Dotters-Katz SK; Goodnight WH; Manuck TA
Am J Obstet Gynecol; 2017 Sep; 217(3):371.e1-371.e7. PubMed ID: 28526452
[TBL] [Abstract][Full Text] [Related]
31. Nonresponse to 17-alpha hydroxyprogesterone caproate for recurrent spontaneous preterm birth prevention: clinical prediction and generation of a risk scoring system.
Manuck TA; Stoddard GJ; Fry RC; Esplin MS; Varner MW
Am J Obstet Gynecol; 2016 Nov; 215(5):622.e1-622.e8. PubMed ID: 27418444
[TBL] [Abstract][Full Text] [Related]
32. 17 alpha-hydroxyprogesterone caproate does not prolong pregnancy or reduce the rate of preterm birth in women at high risk for preterm delivery and a short cervix: a randomized controlled trial.
Winer N; Bretelle F; Senat MV; Bohec C; Deruelle P; Perrotin F; Connan L; Vayssière C; Langer B; Capelle M; Azimi S; Porcher R; Rozenberg P;
Am J Obstet Gynecol; 2015 Apr; 212(4):485.e1-485.e10. PubMed ID: 25448515
[TBL] [Abstract][Full Text] [Related]
33. Plasma CRH measurement at 16 to 20 weeks' gestation does not predict preterm delivery in women at high-risk for preterm delivery.
Sibai B; Meis PJ; Klebanoff M; Dombrowski MP; Weiner SJ; Moawad AH; Northen A; Iams JD; Varner MW; Caritis SN; O'Sullivan MJ; Miodovnik M; Leveno KJ; Conway D; Wapner RJ; Carpenter M; Mercer B; Ramin SM; Thorp JM; Peaceman AM; Gabbe S;
Am J Obstet Gynecol; 2005 Sep; 193(3 Pt 2):1181-6. PubMed ID: 16157134
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of 17α-hydroxyprogesterone caproate in prevention of preterm delivery.
Saghafi N; Khadem N; Mohajeri T; Shakeri MT
J Obstet Gynaecol Res; 2011 Oct; 37(10):1342-5. PubMed ID: 21564406
[TBL] [Abstract][Full Text] [Related]
35. Does progesterone treatment influence risk factors for recurrent preterm delivery?
Meis PJ; Klebanoff M; Dombrowski MP; Sibai BM; Leindecker S; Moawad AH; Northen A; Iams JD; Varner MW; Caritis SN; O'Sullivan MJ; Miodovnik M; Leveno KJ; Conway D; Wapner RJ; Carpenter M; Mercer B; Ramin SM; Thorp JM; Peaceman AM; Gabbe S
Obstet Gynecol; 2005 Sep; 106(3):557-61. PubMed ID: 16135587
[TBL] [Abstract][Full Text] [Related]
36. Quantitative fetal fibronectin screening in asymptomatic high-risk patients and the spectrum of risk for recurrent preterm delivery.
Kurtzman J; Chandiramani M; Briley A; Poston L; Das A; Shennan A
Am J Obstet Gynecol; 2009 Mar; 200(3):263.e1-6. PubMed ID: 19254585
[TBL] [Abstract][Full Text] [Related]
37. The use of progestational agents for preterm birth: lessons from a mouse model.
Elovitz MA; Mrinalini C
Am J Obstet Gynecol; 2006 Oct; 195(4):1004-10. PubMed ID: 17000233
[TBL] [Abstract][Full Text] [Related]
38. 17α Hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
Merlob P; Stahl B; Klinger G
Reprod Toxicol; 2012 Jan; 33(1):15-9. PubMed ID: 22120850
[TBL] [Abstract][Full Text] [Related]
39. Clinical and economic outcomes of preterm labor management: inpatient vs outpatient.
Ambrose S; Rhea DJ; Istwan NB; Collins A; Stanziano G
J Perinatol; 2004 Aug; 24(8):515-9. PubMed ID: 15141268
[TBL] [Abstract][Full Text] [Related]
40. Management of recurrent preterm labor in twin gestations with nifedipine tocolysis.
de la Torre L; Istwan NB; Desch C; Rhea DJ; Roca L; Stanziano GJ; González-Quintero VH
Am J Perinatol; 2008 Oct; 25(9):555-60. PubMed ID: 18773381
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]